Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by RENO911on Jan 14, 2020 12:56pm

62 Views

Post# 30551554

Ask yourself

Why DebbieChandler has to make a new account every single day. This idiot posts garbage that gets deleted within a 24 hour period. When IT arrived early last year, it was spewing information that the company was in debt 25million (no proof to back up this info). By end of summer this ammount grew to 50million (again no proof to back up this info). And now all of a sudden its at 75million!

All the info is in the Sadar reports. Don't take a single word IT is saying as truthful. IT has an adgenda and that adgenda is to keep the price at the lowest possible. I firmly believe IT has been brought here by either a potential buyer or potential market competitor.

Bullboard Posts

Bombardier delivers Global 6500 aircraft to U.S. Army